References
Bechara A, Casabe A (2014) Rodriguez Baigorri G, Cobreros C. Effectiveness of tadalafil 5 mg once daily in the treatment of men with lower urinary tract symptoms suggestive to benign prostatic hyperplasia with or without erectile dysfunction: results from naturalistic observational TadaLutsEd study. J Sex Med 11(2):498–505
Tsertsvadze A, Yazdi F, Fink HA et al (2009) Rockville (MD): diagnosis and treatment of erectile dysfunction. Evidence reports/Technology Assessments, No. 171. Agency for Healthcare Research and Quality (US)
Hazell L, Cornelius V, Wilton LV, Shakir SA (2009) The safety profile of tadalafil as prescribed in general practice in England: results from a prescription-event monitoring study involving 16 129 patients. BJU Int 103(4):506–514
Arnold AC, Costa RM, Dumitrascu OM (2013) The spectrum of optic disc ischemia in patients younger than 50 years (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 111:93–118
Cahill KB, Quade JH, Carleton KL, Cote RH (2012) Identification of amino acid residues responsible for selectivity of tadalafil binding of two closely related phosphodiesterases, PDE5 and PDE6. J Biol Chem 287(49):41406–41416
Acknowledgments
We would like to thank Dr. Cristina Scarpazza for thoughtful comments on this work.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors reported no conflict of interest.
Rights and permissions
About this article
Cite this article
Cordioli, C., Capra, R. Bilateral visual loss recovering after tadalafil withdrawal. Neurol Sci 37, 809–810 (2016). https://doi.org/10.1007/s10072-015-2447-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-015-2447-z